Products for Research Use Only
RegisterLogin

Berberine (hemisulfate)

CAT: 0804-HY-N0716A-01Size: 25 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-N0716A-01Size:25 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Berberine hemisulfate is the hemisulfate form of Berberine. Berberine hemisulfate is an alkaloid isolated from the Chinese herbal medicine Huanglian. Berberine hemisulfate exhibits anti-inflammatory, antibiobic, antitumor, cardiovascular protective and neuroprotective activity[1][2][3][4][5][6].
CAS Number
316-41-6
Product Name Alternative
Natural Yellow 18 (hemisulfate)
UNSPSC
12352005
Hazard Statement
H301+H311+H331
Target
Akt; Antibiotic; AP-1; Apoptosis; Autophagy; Bacterial; Caspase; JNK; NF-κB; PI3K; Reactive Oxygen Species (ROS) ; Topoisomerase
Type
Natural Products
Related Pathways
Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Cancer; Infection; Metabolic Disease; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/berberine-hemisulfate.html
Purity
99.63
Solubility
DMSO : 2 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 200 mg/mL (ultrasonic)
Smiles
O=S([O-])([O-])=O.COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C=C2C=C1.[0.5]
Molecular Formula
C20H18NO4.1/2O4S
Molecular Weight
384.40
Precautions
H301+H311+H331
References & Citations
[1]Cai Y, et al. Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. J Nat Med. 2014 Jan;68 (1) :53-62.|[2]Cui HX, et al. Preparation and Evaluation of Antidiabetic Agents of Berberine Organic Acid Salts for Enhancing the Bioavailability. Molecules. 2018 Dec 28;24 (1) :103.|[3]Boberek JM, et al., Genetic evidence for inhibition of bacterial division protein FtsZ by berberine. PLoS One. 2010 Oct 29;5 (10) :e13745. |[4]Remppis A, et al., Rhizoma Coptidis inhibits LPS-induced MCP-1/CCL2 production in murine macrophages via an AP-1 and NFkappaB-dependent pathway. Mediators Inflamm. 2010;2010:194896.|[5]Bae J, et al., Berberine protects 6-hydroxydopamine-induced human dopaminergic neuronal cell death through the induction of heme oxygenase-1. Mol Cells. 2013 Feb;35 (2) :151-7. |[6]Ye Y, et al., Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Pharmacol. 2021 Apr 26;12:653887.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Natural Products
Clinical Information
Launched
Citation 01
Phytomedicine. 2024 Dec:135:156111.|Acta Pharmacol Sin. 2023 Feb;44 (2) :332-344.|Appl Biochem Biotechnol. 2024 Aug;196 (8) :5265-5282.|Aquaculture. 15 May 2022, 738055.|Biol Pharm Bull. 2022 Oct 1;45 (10) :1444-1451.|Biomed Pharmacother. 2024 Jan:170:116012.|BMC Pharmacol Toxicol. 2023 May 11;24 (1) :29.|Cell Stem Cell. 2025 May 1;32 (5) :778-794.e10.|Evid Based Complement Alternat Med. 2021 May 4:2021:6688629.|Exp Cell Res. 2020 Aug 1;393 (1) :112054.|Exp Cell Res. 2024 May 13:114094.|Fish Shellfish Immunol. 2024 Jun:149:109522.|Food Chem Toxicol. 2023 May:175:113743.|Gene. 2022 Mar 30:816:146171.|Genome Instab Dis. 2025 Mar.|Hepatol Commun. 2024 Mar 29;8 (4) :e0405.|Int J Nanomedicine. 2023 Jul 31:18:4347-4363.|J Bone Miner Metab. 2021 Sep;39 (5) :748-756.|J Cell Mol Med. 2025 Sep;29 (17) :e70836.|J Ethnopharmacol. 2022 Mar 1:285:114786.|J Ethnopharmacol. 2024 Apr 24:324:117829.|J Inflamm Res. 2025 Aug 21:18:11451-11461.|J Pharm Pharmacol. 2022 Sep 1;74 (9) :1353-1363.|JCI Insight. 2023 Jul 24;8 (14) :e166306.|Microb Pathog. 2025 Dec:209:108114.|Mol Med Rep. 2023 Jan;27 (1) :17.|Mol Med. 2024 Dec 20;30 (1) :251.|Pharm Biol. 2024 Dec;62 (1) :53-61.|Phytomedicine. 2024 Jan:123:155247.|Phytomedicine. 2025 Sep 4:148:157233.|Res Sq. 2025 Apr 15.|Research Square Preprint. 2021 Jun.|Research Square Preprint. 2021 Sep.|Sci Rep. 2022 Oct 17;12 (1) :17350.|Sci Rep. 2025 Jul 1;15 (1) :21623.|SSRN. 2023 Jan 27.|Toxicol Appl Pharmacol. 2025 Sep 13:505:117563.|Toxicol In Vitro. 2025 Dec:109:106128.|Cardiovasc Drugs Ther. 2022 Aug;36 (4) :633-643.|J Appl Microbiol. 2021 Apr;130 (4) :1154-1172.|Microbiol Spectr. 2023 Sep 25;11 (5) :e0217023.|NPJ Biofilms Microbiomes. 2025 Jul 1;11 (1) :120.|NPJ Sci Food. 2025 Feb 4;9 (1) :16.|Int Immunopharmacol. 2024 May 30:133:112036.|Mol Reprod Dev. 2024 Aug;91 (8) :e23768.|NPJ Sci Food. 2025 Feb 4;9 (1) :16.

Related Products

CatalogName
HY-N0716Berberine
HY-147246-01Berberine ursodeoxycholate
HY-18258-01Berberine (chloride)
HY-N0716B-01Berberine (sulfate)
HY-W995025AActinobolin (hemisulfate)
HY-B1276-01Metaproterenol (hemisulfate)
HY-W020772-01Aminoguanidine (hemisulfate)
HY-12689BMitapivat (hemisulfate)
HY-137958-01Bemnifosbuvir (hemisulfate)
HY-B1624A-01Debrisoquin (hemisulfate)

Alternative Products

CatalogName
sc-202496Berberine hemisulfate
217216Berberine Chloride (Berberine)
217215Berberine Chloride (Berberine) discontinued
SM4136-100mgBerberine

Popular Products